

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

JAN - 2 2008

Office of Regulatory Policy HFD-7 5600 Fishers Lane (Rockwall II Rm 1101) Rockville, MD 20857

Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 6,605,599 was filed on November 15, 2007, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, IXEMPRATM (ixabepilone), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner

for Patent Examination Policy

cc:

Anastasia P. Winslow Patent Department Bristol-Myers Squibb Co. P.O. Box 4000

Princeton, NJ 08543-4000